Dr.PulmRoch said:The pattern that distinguishes a bad batch from an exit is behaviour rather than product.
All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.
pat_auckland said:Steady state is the thing most people miss.
Genuinely useful, thank you. I had the facts and not the framework. Adding it to my notes with a link back to this thread.
Dr.PulmRoch said:The pattern that distinguishes a bad batch from an exit is behaviour rather than product.
Pushing back on Dr.PulmRoch here. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.
Worth separating that from vendor vetting, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsThe figures, for anyone assembling their own picture. Red flags, in rough order of how much they should worry you: no verifiable address, no batch numbers, prices far under market, vendor-commissioned tests only, pressure toward irreversible payment, and shipping with no temperature control.